Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

Completed · Phase 4

Conditions studied: Delayed Graft Function

In brief

Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF. Ongoing research in animal models has demonstrated benefit with administration of erythropoietin. The investigators propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.

Key facts

Study ID

NCT00425126

Run by

West Penn Allegheny Health System

People needed

76

Starts

2007-02-01

Expected to finish

2010-02-01

Last updated by the study team

2010-05-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients presenting for kidney transplantation
• Age > 18
• Deceased donor kidney transplant

You may not qualify if…

• History of thrombosis or hypercoagulable state
• Receiving Coumadin or Heparin
• Hemoglobin >=14 g/dl
• Uncontrolled hypertension

Where it is running

• Allegheny General Hospital — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.